542 related articles for article (PubMed ID: 11288792)
21. Enamel matrix derivative versus bioactive ceramic filler in the treatment of intrabony defects: 12-month results.
Leknes KN; Andersen KM; Bøe OE; Skavland RJ; Albandar JM
J Periodontol; 2009 Feb; 80(2):219-27. PubMed ID: 19186961
[TBL] [Abstract][Full Text] [Related]
22. Five-year results evaluating the effects of platelet-rich plasma on the healing of intrabony defects treated with enamel matrix derivative and natural bone mineral.
Döri F; Arweiler N; Húszár T; Gera I; Miron RJ; Sculean A
J Periodontol; 2013 Nov; 84(11):1546-55. PubMed ID: 23327604
[TBL] [Abstract][Full Text] [Related]
23. Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of infrabony defects: a comparative controlled clinical trial.
Zucchelli G; Bernardi F; Montebugnoli L; De SM
J Periodontol; 2002 Jan; 73(1):3-12. PubMed ID: 11846197
[TBL] [Abstract][Full Text] [Related]
24. Treatment of intrabony defects using guided tissue regeneration or enamel matrix derivative: a 3-year prospective randomized clinical study.
Crea A; Dassatti L; Hoffmann O; Zafiropoulos GG; Deli G
J Periodontol; 2008 Dec; 79(12):2281-9. PubMed ID: 19053918
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of demineralized freeze-dried bone allograft with and without enamel matrix derivative for the treatment of periodontal osseous defects in humans.
Hoidal MJ; Grimard BA; Mills MP; Schoolfield JD; Mellonig JT; Mealey BL
J Periodontol; 2008 Dec; 79(12):2273-80. PubMed ID: 19053917
[TBL] [Abstract][Full Text] [Related]
26. Effect of platelet-rich plasma on the healing of intrabony defects treated with an enamel matrix protein derivative and a natural bone mineral.
Döri F; Nikolidakis D; Húszár T; Arweiler NB; Gera I; Sculean A
J Clin Periodontol; 2008 Jan; 35(1):44-50. PubMed ID: 18034853
[TBL] [Abstract][Full Text] [Related]
27. Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial.
Sanz M; Tonetti MS; Zabalegui I; Sicilia A; Blanco J; Rebelo H; Rasperini G; Merli M; Cortellini P; Suvan JE
J Periodontol; 2004 May; 75(5):726-33. PubMed ID: 15212355
[TBL] [Abstract][Full Text] [Related]
28. Bioabsorbable membrane and bioactive glass in the treatment of intrabony defects in patients with generalized aggressive periodontitis: results of a 12-month clinical and radiological study.
Mengel R; Soffner M; Flores-de-Jacoby L
J Periodontol; 2003 Jun; 74(6):899-908. PubMed ID: 12887004
[TBL] [Abstract][Full Text] [Related]
29. Enamel matrix derivative in the treatment of human intrabony osseous defects.
Okuda K; Momose M; Miyazaki A; Murata M; Yokoyama S; Yonezawa Y; Wolff LF; Yoshie H
J Periodontol; 2000 Dec; 71(12):1821-8. PubMed ID: 11156038
[TBL] [Abstract][Full Text] [Related]
30. Four-year results following treatment of intrabony periodontal defects with an enamel matrix derivative alone or combined with a biphasic calcium phosphate.
Pietruska M; Pietruski J; Nagy K; Brecx M; Arweiler NB; Sculean A
Clin Oral Investig; 2012 Aug; 16(4):1191-7. PubMed ID: 21881869
[TBL] [Abstract][Full Text] [Related]
31. Effects of pretreatment clinical parameters on bioactive glass implantation in intrabony periodontal defects.
Park JS; Suh JJ; Choi SH; Moon IS; Cho KS; Kim CK; Chai JK
J Periodontol; 2001 Jun; 72(6):730-40. PubMed ID: 11453234
[TBL] [Abstract][Full Text] [Related]
32. Effect of platelet-rich plasma on the healing of intrabony defects treated with Beta tricalcium phosphate and expanded polytetrafluoroethylene membranes.
Döri F; Huszár T; Nikolidakis D; Tihanyi D; Horváth A; Arweiler NB; Gera I; Sculean A
J Periodontol; 2008 Apr; 79(4):660-9. PubMed ID: 18380559
[TBL] [Abstract][Full Text] [Related]
33. Clinical performance of a regenerative strategy for intrabony defects: scientific evidence and clinical experience.
Cortellini P; Tonetti MS
J Periodontol; 2005 Mar; 76(3):341-50. PubMed ID: 15857066
[TBL] [Abstract][Full Text] [Related]
34. Enamel matrix proteins in the treatment of deep intrabony defects.
Cardaropoli G; Leonhardt AS
J Periodontol; 2002 May; 73(5):501-4. PubMed ID: 12027251
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of a biphasic calcium composite grafting material in the treatment of human periodontal intrabony defects: a 12-month randomized controlled clinical trial.
Stein JM; Fickl S; Yekta SS; Hoischen U; Ocklenburg C; Smeets R
J Periodontol; 2009 Nov; 80(11):1774-82. PubMed ID: 19905932
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes following regenerative therapy of non-contained intrabony defects using a deproteinized bovine bone mineral combined with either enamel matrix derivative or collagen membrane.
Iorio-Siciliano V; Andreuccetti G; Blasi A; Matarasso M; Sculean A; Salvi GE
J Periodontol; 2014 Oct; 85(10):1342-50. PubMed ID: 24835417
[TBL] [Abstract][Full Text] [Related]
37. Enamel matrix proteins in the regenerative therapy of deep intrabony defects.
Tonetti MS; Lang NP; Cortellini P; Suvan JE; Adriaens P; Dubravec D; Fonzar A; Fourmousis I; Mayfield L; Rossi R; Silvestri M; Tiedemann C; Topoll H; Vangsted T; Wallkamm B
J Clin Periodontol; 2002 Apr; 29(4):317-25. PubMed ID: 11966929
[TBL] [Abstract][Full Text] [Related]
38. Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study.
Wachtel H; Schenk G; Böhm S; Weng D; Zuhr O; Hürzeler MB
J Clin Periodontol; 2003 Jun; 30(6):496-504. PubMed ID: 12795787
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of wound healing following multiple exposures to enamel matrix protein derivative in the treatment of intrabony periodontal defects.
Heard RH; Mellonig JT; Brunsvold MA; Lasho DJ; Meffert RM; Cochran DL
J Periodontol; 2000 Nov; 71(11):1715-21. PubMed ID: 11128919
[TBL] [Abstract][Full Text] [Related]
40. Supracrestal soft tissue preservation with enamel matrix proteins in treatment of deep intrabony defects.
Trombelli L; Bottega S; Zucchelli G
J Clin Periodontol; 2002 May; 29(5):433-9. PubMed ID: 12060426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
